Jian Irish - 01 Apr 2026 Form 4 Insider Report for Metagenomi Therapeutics, Inc. (MGX)

Reporting relationship: Title: President and Chief Executive Officer, Director
Issuer ticker: MGX
Reported as of: 01 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Apr 2026, 14:11:59 UTC
Prior SEC filing: 09 Mar 2026
Next SEC filing: 10 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Matthew L. Wein, attorney-in-fact

Key filing fact

Jian Irish filed Form 4 for Metagenomi Therapeutics, Inc. (MGX) on 03 Apr 2026.

Key facts

This page summarizes Jian Irish's Form 4 filing for Metagenomi Therapeutics, Inc. (MGX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Apr 2026, 14:11.

Change

Previous filing in this sequence was filed on 09 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001995697 Primary reporting owner

Irish Jian

Relationship: Title: President and Chief Executive Officer, Director
Address: C/O METAGENOMI THERAPEUTICS, INC., 5959 HORTON STREET, 7TH FLOOR, EMERYVILLE
Signature: /s/ Matthew L. Wein, attorney-in-fact
Signature date: 03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MGX transaction

Common Stock

Award

Transaction value
Shares: +46,000
Change %: +14%
Price: $0.000000^*
Shares after: 379,770
Date: 01 Apr 2026
Ownership: Direct
Footnotes: F1

MGX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 292,714
Date: 01 Apr 2026
Ownership: By Trust
Footnotes: F2

MGX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 292,713
Date: 01 Apr 2026
Ownership: By Trust
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MGX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +276,000
Change %
Price: $0.000000^*
Shares after: 276,000
Date: 01 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 276,000
Exercise price: $1.34
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2027, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

Footnote F2

Shares held by the Bruce Irish 2023 Irrevocable Trust FBO Jian Irish. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F3

Shares held by the Jian Irish 2023 Irrevocable Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F4

25% of the shares subject to this option shall vest and become exercisable on April 1, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date.

SEC remarks

Title: President and Chief Executive Officer